AveXis IPO

2/10/2016

IPO

$95,000,000

Based on our current operational plans and assumptions, we expect that the net proceeds from this offering, combined with our current cash and cash equivalents, will be sufficient to fund operations through 2017 and enable us to initiate our planned pivotal trials of AVXS-101 for SMA Type 1, which we expect to initiate in the first half of 2017, but that we will need to raise additional capital in order to complete those trials and any potential future trials that may be required by regulatory authorities. Our expected use of net proceeds from this offering represents our current intentions based upon our present plans and business condition. As of the date of this prospectus, we cannot predict with complete certainty all of the particular uses for the net proceeds to be received upon the completion of this offering or the actual amounts that we will spend on the uses set forth above. We believe opportunities may exist from time to time to expand our current business through the acquis

Acquired or Merged

Biopharmaceutical

2275 Half Day Rd. 200
Bannockburn, IL 60015
USA

AveXis is focused on developing gene therapy for patients with rare and life-threatening neurological genetic diseases, like spinal muscular atrophy (SMA).